Journal of Thyroid Cancer

01 · Scope

One disease, read across its whole course

Thyroid carcinoma is described by disciplines that rarely share a journal: the laboratory that characterizes the driver mutation, the cytopathologist who reads the aspirate, the radiologist and the surgeon who plan the operation, the nuclear-medicine physician who delivers the radioiodine, and the endocrinologist who follows the patient for decades afterwards. JTC publishes across all of them, and welcomes differentiated, medullary, anaplastic and rare thyroid malignancies alike.

• 01

  Biology and molecular oncology

  Genetic drivers of thyroid malignancy and the signaling they dysregulate: BRAF, RAS and RET/PTC rearrangements, MAPK/ERK and PI3K/AKT/mTOR activation, epigenetic and chromosomal change, hereditary syndromes, the tumor microenvironment, metabolic reprogramming, and the transitions that precede invasion.

• 02

  Diagnosis and risk stratification

  Cytopathology and reporting categories, fine-needle aspiration, ancillary immunocytochemistry, ultrasound characterization and staging imaging, and the molecular testing that resolves indeterminate nodules and the boundary between benign and malignant lesions. Biomarkers for detection, subtype classification, prognosis and recurrence prediction belong here.

• 03

  Surgery and local treatment

  Extent of thyroidectomy, lymph-node management, preoperative evaluation, reoperative surgery and complications, together with percutaneous ablative and image-guided interventional techniques.

• 04

  Radioiodine and nuclear medicine

  Radioiodine selection, dosimetry and ablation practice, post-therapy imaging and radiation safety, diagnostic and theranostic radiopharmaceuticals, and the management of radioiodine-refractory disease.

• 05

  Systemic and targeted therapy

  Kinase and RET-directed agents, resistance mechanisms and companion-diagnostic evidence, external-beam approaches, and immunotherapy where the evidence in thyroid carcinoma supports it.

• 06

  Outcomes, surveillance and survivorship

  Thyroglobulin and antibody follow-up, response-to-therapy reassessment, active surveillance of low-risk disease, recurrence and long-term treatment outcomes, and the endocrine and quality-of-life consequences patients live with afterwards.

Benign thyroid lesions are in scope where they bear on cancer — the indeterminate nodule, differential diagnosis, tumor classification, molecular risk assessment and the surgical decision that follows — rather than as general thyroid disease.

04 · Peer review

How a manuscript is handled

06 · Identifiers, discovery and preservation

How JTC articles are found and kept

JTC uses distinct services to identify articles, distribute metadata, support scholarly discovery, and preserve the published record.

• Journal identifier ISSN 2574-4496

  Registered with the ISSN International Centre and listed in ROAD, its directory of open-access scholarly resources. View the record

• DOI registration Crossref, prefix 10.14302

  JTC uses Crossref to register deposited article identifiers and maintain their citation metadata. View the record

• Metadata harvesting OAI-PMH

  Article metadata is exposed in a standard format for harvesting by libraries, repositories and aggregators.

• Discovery services Google Scholar, OpenAlex and Semantic Scholar

  Google Scholar, OpenAlex and Semantic Scholar make covered article records searchable through crawling and metadata feeds. View the record

• Digital preservation Portico

  This journal's content is committed to Portico, a not-for-profit digital-preservation archive run by ITHAKA (the organization behind JSTOR). As articles are deposited they enter Portico's permanent archive, so the scholarly record stays available for the long term — even if a title one day ceases to publish. Read our preservation policy

08 · Questions authors ask

Before you submit

What does the Journal of Thyroid Cancer publish?

Journal of Thyroid Cancer publishes peer-reviewed mechanistic, translational and clinical research on thyroid carcinoma, across tumor biology, cytologic and molecular diagnosis, imaging, surgery, radioiodine and systemic therapy, and long-term outcomes. Its six territories are biology and molecular oncology; diagnosis and risk stratification; surgery and local treatment; radioiodine and nuclear medicine; systemic and targeted therapy; and outcomes, surveillance and survivorship. Benign thyroid lesions are in scope where they bear on cancer — indeterminate nodules, differential diagnosis, tumor classification and surgical decision-making — rather than as general thyroid disease.

Who publishes JTC, and under what terms?

JTC is published by Open Access Pub under ISSN 2574-4496. Articles are open access under the Creative Commons Attribution 4.0 license, with copyright retained by the authors. Published records display a Crossref DOI under the prefix 10.14302 when one is registered.

How are manuscripts reviewed?

All submissions undergo initial editorial screening. Manuscripts that meet the journal's scope and minimum requirements proceed to independent peer review. Single-blind by default; double-blind review is available on request. Manuscripts that proceed to external peer review are normally evaluated by at least two independent subject-matter experts. Editorial decisions are based on scope, scientific quality, methodological rigor, ethical compliance, reporting quality, and relevance to the journal.

Who provides editorial oversight?

Editorial oversight rests with an Editor-in-Chief and an editorial board of 15 members across 11 countries, of whom 10 publish an ORCID iD. The board covers endocrinology, endocrine surgery, nuclear medicine, interventional radiology, cytopathology, molecular oncology and cancer epidemiology.

What does it cost to publish in JTC?

There is no submission fee and no reader charge. An article processing charge falls due only after a manuscript has been accepted, and it is set by article type, from USD 1,600 to USD 1,800. Original research is USD 1,800. Charges support peer-review coordination, editorial management, production, DOI registration and long-term archiving. Billing and fee-relief administration is separate from editorial decisions.

How do I submit a manuscript?

There are three routes to one editorial office: ManuscriptZone as the primary route, the simple manuscript submission form as an alternative, and assisted submission by email to [email protected]. Authors must use only one submission route for the same manuscript.